Table 5.
Economic Outcomes of the Heart Failure Subgroup
| Heart Failure Subgroup | Catheter Ablation | Drug Therapy | Difference | Incremental Cost Effectiveness Ratio | Probability of Cost-Effectiveness |
||
|---|---|---|---|---|---|---|---|
| $50,000 | $100,000 | $150,000 | |||||
| Base Case | |||||||
| Lifetime Costs, USD | 182,463 (151,803, 203,144) |
147,204 (116,990, 166,117) |
35,259 (−2,463, 74,666) |
-- | |||
| QALYs | 9.96 (9.66, 10.26) |
9.31 (8.99, 9.64) |
0.65 (0.26, 1.05) |
$54,135 per QALY | 44% | 85% | 96% |
| LYs | 11.89 (11.53, 12.25) |
11.36 (10.97, 11.75) |
0.53 (0.06, 1.01) |
$70,907 per LY | 35% | 72% | 86% |
|
| |||||||
| Attenuated QoL Benefit † | |||||||
| QALYs | 9.91 (9.61, 10.21) |
9.36 (9.04, 9.69) |
0.54 (0.15, 0.95) |
$64,720 per QALY | 35% | 75% | 90% |
†
Attenuated QOL benefit – This sensitivity analysis assumes a conservative scenario where the catheter ablation group does not gain any quality-of-life benefits beyond the end of the trial (5-years). Similar to the base case, this analysis did not allow the catheter ablation group to accumulate additional life years compared to the drug group since the within-trial analysis does not support a mortality benefit with ablation by intention-to-treat. That is, the hazard ratio of mortality (catheter ablation versus drug therapy) is set to 1.0 beyond 5 years.
Abbreviations: LY – life year; QALY – quality-adjusted life year; QoL – quality of life; USD – United States dollar.